

## KAPITEL 8      Anhang I

### Humane Schnittstellendaten

TABELLE 29. Humane Schnittstellen (Swissprot ID) mit Referenzen der experimentellen Überprüfungen.

ID	neues Signal	Swissprot Signal	Referenz
A2AP		1-27	FEBS LETT 312:100-104(1992).
ANT3		1-32	STRUCTURE 2:257-270(1994).
APC1		1-26	J. BIOL. CHEM. 250:182-190(1975).
APC2		1-22	J. BIOL. CHEM. 259:318-322(1984).
APOH		1-19	PROC. NATL. ACAD. SCI. U.S.A. 81:3640-3644(1984).
C1S	1-14	1-15	EUR. J. BIOCHEM. 156:49-57(1986).
CA14		1-27	EUR. J. BIOCHEM. 152:213-219(1985).
CAML		1-19	J. BIOL. CHEM. 263:11943-11947(1988).
CAP7		1-26	FEBS LETT. 272:200-204(1990).
CBG		1-22	J. STEROID BIOCHEM. 29:213-220(1988).
CBPM	1-10	<1-13	J. BIOL. CHEM. 264:13165-13170(1989).
CERU		1-19	PROC. NATL. ACAD. SCI. U.S.A. 81:390-394(1984).
CFAB		1-25	J. BIOL. CHEM. 259:3407-3412(1984).
CHLE		1-28	J. BIOL. CHEM. 262:549-557(1987).
CO6		1-21	J. BIOL. CHEM. 264:18041-18051(1989).
DAF		1-34	BIOCHIM. BIOPHYS. ACTA 1074:326-330(1991).
EGLN	1-8	<1-12	J. BIOL. CHEM. 265:8361-8364(1990).
FGF7		1-31	SCIENCE 245:752-755(1989).
FIBA		1-19	BIOCHEMISTRY 18:5410-5416(1979).
FINC		1-31	J. BIOL. CHEM. 258:12670-12674(1983).
GLHA		1-24	J. BIOL. CHEM. 250:6735-6746(1975).
GLPB		1-19	J. BIOL. CHEM. 262:5808-5811(1987).
GLYP		1-23	J. CELL BIOL. 111:3165-3176(1990).
GONL		1-23	BIOCHEM. BIOPHYS. RES. COMMUN. 109:1061-1071(1982).

TABELLE 29. Humane Schnittstellen (Swissprot ID) mit Referenzen der experimentellen Überprüfungen.

ID	neues Signal	Swissprot Signal	Referenz
GP39		1-21	J. BIOL. CHEM. 268:25803-25810(1993).
HA2R		1-25	HOPPE-SEYLER'S Z. PHYSIOL. CHEM. 363:671-676(1982).
HEP2		1-19	BIOCHEMISTRY 24:6777-6782(1985).
HIS1		1-19	J. BIOL. CHEM. 263:7472-7477(1988).
I12B		1-22	PROC. NATL. ACAD. SCI. U.S.A. 87:6808-6812(1990).
INA2		1-23	NATURE 287:408-411(1980).
ING		1-20	J. BIOL. CHEM. 259:6790-6797(1984).
INS		1-24	NATURE 187:483-485(1960).
ITA2		1-29	J. CELL BIOL. 109:397-407(1989).
ITAX		1-19	J. IMMUNOL. 138:2381-2383(1987).
LCA		1-19	EUR. J. BIOCHEM. 27:65-86(1972).
LIPG		1-19	EUR. J. BIOCHEM. 182:495-499(1989).
LITA		1-22	BIOCHIM. BIOPHYS. ACTA 994:281-284(1989).
LMP1		1-27	J. BIOL. CHEM. 263:18920-18928(1988).
LMP2		1-28	J. BIOL. CHEM. 263:18920-18928(1988).
LU		1-31	PROC. NATL. ACAD. SCI. U.S.A. 92:5496-5500(1995).
LYC		1-18	HELV. CHIM. ACTA 54:2668-2675(1971).
MDP1		1-16	BIOCHEM. J. 265:429-433(1990).
MU18		1-23	CANCER RES. 54:2514-2520(1994).
OMGP		1-24	J. CELL BIOL. 106:1273-1279(1988).
PA2M		1-20	BIOCHEM. BIOPHYS. RES. COMMUN. 163:42-48(1989).
PEPA	1-14	1-15	J. BIOCHEM. 106:920-927(1989).
PEPC		1-16	J. BIOCHEM. 106:920-927(1989).
PLTP		1-17	J. BIOL. CHEM. 269:9388-9391(1994).
PPA5		1-21	BIOCHEM. BIOPHYS. RES. COMMUN. 168:792-800(1990).
PPBT		1-17	ARCH. BIOCHEM. BIOPHYS. 245:331-337(1986).
PRL		1-28	J. BIOL. CHEM. 250:3629-3636(1975).
PS2		1-24	BIOCHEM. BIOPHYS. RES. COMMUN. 155:366-372(1988).
PSSP		1-20	BIOCHEM. BIOPHYS. RES. COMMUN. 180:356-359(1991).
PTHY		1-25	NATURE 249:155-157(1974).
PTN		1-32	J. BIOL. CHEM. 267:2582-2587(1992).
REL2		1-24	J. BIOL. CHEM. 266:10754-10761(1991).
SAA		1-18	BIOCHEM. J. 282:615-620(1992).
SAMP		1-19	J. BIOL. CHEM. 260:12895-12898(1985).
SAP3		1-31	EUR. J. BIOCHEM. 192:709-714(1990).
SG1		1-20	REGUL. PEPT. 33:223-235(1991).
SOMA		1-26	J. BIOL. CHEM. 256:2395-2401(1981).

TABELLE 29. Humane Schnittstellen (Swissprot ID) mit Referenzen der experimentellen Überprüfungen.

ID	neues Signal	Swissprot Signal	Referenz
SPRC		1-17	J. BIOL. CHEM. 262:9702-9708(1987).
STS		1-21	BIOCHIM. BIOPHYS. ACTA 997:199-205(1989).
TCO2		1-18	J. BIOL. CHEM. 261:15455-15460(1986).
TENA		1-22	NUCLEIC ACIDS RES. 19:525-531(1991).
THBG		1-20	BIOCHEM. BIOPHYS. RES. COMMUN. 79:1212-1218(1977).
TIM1		1-23	FEBS LETT. 296:16-20(1992).
TRFL		1-19	EUR. J. BIOCHEM. 145:659-666(1984).
TRY2	1-14	1-15	CLIN. CHIM. ACTA 184:31-46(1989).
TRYA		1-30	J. BIOL. CHEM. 262:1363-1373(1987).
TTHY		1-20	J. BIOL. CHEM. 249:6796-6805(1974).
UROK		1-20	HOPPE-SEYLER'S Z. PHYSIOL. CHEM. 363:1155-1165(1982).
VEGF		1-26	EUR. J. BIOCHEM. 211:19-26(1993).
VTDB		1-16	BIOCHIM. BIOPHYS. ACTA 871:189-198(1986).
VTNC		1-19	FEBS LETT. 87:55-60(1978).
ZA2G		1-17	PROC. NATL. ACAD. SCI. U.S.A. 85:679-683(1988).

TABELLE 30. Aufteilung der Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swissprot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
PCSVFSPVSAME	A2AP	LGLLSGGVTTTP	CFAB	VLEGPAPAQGTP	APC1
LIGFWDCVTCHG	ANT3	VLLCLPAVWGDC	DAF	LLVLGFVEVQGTQ	APC2
SSFLCHVAIAGR	APOH	SCSLSPTS LAET	EGLN	SRAGSSPLLDIV	CAP7
LFSLLAWVYAEF	C1S	LISVLGTTHGLF	LIPG	LGLLLPLVAALD	CBPM
LHEEHSRAAAKG	CA14	LLAAHPDAQAEV	LU	LCMLIGKSHTED	CHLE
PLLLCSPCLLIQ	CAML	LLFLTPGILCIC	OMGP	LNALINKGQACF	CO6
PTSGLWTVQAMD	CBG	NLLLCQSVAPLP	PRL	LSVFLHVLHSAP	GLHA
LFLCSTPAWAKE	CERU	VSMLALGTLAEA	PS2	AAALVACARGDP	GLYP
ICLVGTISLACN	FGF7	LLNQFSRAVADS	REL2	LTWCVEGCSSQH	GONL
VLSVVGTAWTAD	FIBA	FCSLVLGVSSRS	SAA	IFLIITSAWGGG	HEP2
PSTGASKSKRQA	FINC	QAHLKKPSQLSS	SAP3	LALMISMISADS	HIS1
LLSEIVSISALS	GLPB	GAVGLAAVNSMP	SG1	LVFLASPLVAIW	I12B
VLVLLQCCSAYK	GP39	CLPWLQEGSAFP	SOMA	LSCKSSCSVGC	INA2
VLMSAQESWAIK	HA2R	LLWLIAPSRACT	TIM1	QLCIVLGS LGCY	ING
SQGILNCCLAYN	ITA2	ILTFVAAA VAAP	TRY2	ALWGPDPAAAFV	INS
VGILFPAILAKQ	LCA	LAGLVFVSEAGP	TTHY	LFTALATSLGFN	ITAX
CLMFLSQSQGQE	LITA	CVLVVSDSKGSN	UROK	AARPHALSSAAM	LMP1

TABELLE 30. Aufteilung der Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swisshot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
LWSLVAVCTADF	MDP1	YLHHAKWSQAAP	VEGF	LVLGAVRSYALE	LMP2
VLVCLQLLEAAV	PEPC	LLLAFAFGHALE	VTDB	LVLVSVTVQGV	LYC
ALLLPSLADGAT	PPA5			ACCCCPRVAGVP	MU18
AICFLTKSDGKS	PTHY			MIFGLLQAHGNL	PA2M
LLFFLWEAESHA	STS			LLGLVALSECIM	PEPA
VLGLHATHCAS	THBG			LAIGTCLTNSLV	PPBT
FLGALGLCLAGR	TRFL			FATFVTLCNASC	PSSP
LALLAWVALADQ	VTNC			ILAAVDTAEGAK	PTN
LLLLLGPVAPQE	ZA2G			VLTSLEAFAHT	SAMP
				LLCLAGRALAAP	SPRC
				FLLGVLGALTEM	TCO2
				LAFLALATEGGV	TENA
				APVQALQQAGIV	TRYA
				FLALLAGAHAEF	PLTP

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swisshot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
CSVFSVPSAMEP	A2AP	VFSVPSAMEPLG	A2AP	FSPVPSAMEPLGR	A2AP
SVFSVPSAMEPL	A2AP	PVSAMEPLGRQL	A2AP	VSAMEPLGRQLT	A2AP
SPVPSAMEPLGRQ	A2AP	SAMEPLGRQLTS	A2AP	MEPLGRQLTSGP	A2AP
AMEPLGRQLTSG	A2AP	GFWDVCTCHGSP	ANT3	LEGPAPAQGTDP	APC1
IGFWDVCTCHGS	ANT3	FWDVCTCHGSPV	ANT3	GPAPAQGTDPVSS	APC1
DCVCTCHGSPVDI	ANT3	WDCVCTCHGSPVD	ANT3	PAPAQGTDPVSS	APC1
VTCHGSPVDICT	ANT3	CVTCHGSPVDIC	ANT3	QGTPDVSSALDK	APC1
CHGSPVDICTAK	ANT3	TCHGSPVDICTA	ANT3	EVQGTQQPQQDE	APC2
HGSPVDICTAKP	ANT3	EGPAPAQGTDPV	APC1	GTQQPQQDEMPS	APC2
VLGFVQGTQQP	APC2	APAQGTDPVSSA	APC1	CHVAIAGRTCPC	APOH
QGTQQPQQDEMP	APC2	PAQGTDPVSSAL	APC1	VAIAGRTCPCPKD	APOH
TQQPQQDEMPSP	APC2	AQGTDPVSSALD	APC1	IAGRTCPCPKDDL	APOH
FLCHVAIAGRTC	APOH	GTPDVSSALDKL	APC1	GRTCPCPKDDLPF	APOH
LLAWVYAEPTMY	C1S	TPDVSSALDKLK	APC1	FSLAWVYAEPT	C1S
WVYAEPTMYGEI	C1S	LVLGFVQGTQQ	APC2	AWVYAEPTMYGE	C1S
YAEPTMYGEILS	C1S	LGFEVQGTQQPQ	APC2	AAKGGCAGSGCG	CA14
EEHSRAAAKGGC	CA14	GFEVQGTQQPQQ	APC2	AKGGCAGSGCGK	CA14
EHSRAAAKGGCA	CA14	FEVQGTQQPQQD	APC2	LLCSPCLLIQIP	CAML
HSRAAAKGGCAG	CA14	VQGTQQPQQDEM	APC2	CSPCLLIQIPEE	CAML

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swissprot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
SRAAAKGGCAGS	CA14	SFLCHVAIAGRT	APOH	PCLLIQIPEEYE	CAML
LLLCSPCLLIQI	CAML	LCHVAIAGRTCP	APOH	RAGSSPLLDIVG	CAP7
LCSPCLLIQIPE	CAML	HVAIAGRTCPKP	APOH	GSSPLLDIVGGR	CAP7
SPCLLIQIPEEY	CAML	AIAGRTCPKPDD	APOH	PLLDIVGGRKAR	CAP7
LLIQIPEEYEGH	CAML	AGRTCPKPDDL	APOH	DIVGGRKARPRQ	CAP7
LIQIPEEYEGHH	CAML	SLLAWVYAEPTM	C1S	IVGGRKARPRQF	CAP7
IQIPEEYEGHHV	CAML	LAWVYAEPTMYG	C1S	TVQAMPNAAAYV	CBG
AGSSPLLDIVGG	CAP7	VYAEPTMYGEIL	C1S	QAMPNAAAYVNM	CBG
SSPLLDIVGGRK	CAP7	AEPTMYGEILSP	C1S	AMPNAAAYVNMS	CBG
LLDIVGGRKARP	CAP7	EPTMYGEILSPN	C1S	LLLPLVAALDFN	CBPM
TSGLWTVQAMP	CBG	HEEHSRAAAKGG	CA14	LLPLVAALDFNY	CBPM
SGLWTVQAMPDN	CBG	RAAAKGGCAGSG	CA14	LPLVAALDFNYH	CBPM
GLWTVQAMPDPA	CBG	AAAKGGCAGSGC	CA14	LVAALDFNYHRQ	CBPM
WTVQAMPNAAAY	CBG	KGGCAGSGCGKC	CA14	VAALDFNYHRQE	CBPM
MDPNAAAYVNMSN	CBG	CLLIQIPEEYEG	CAML	LDFNYHRQEGME	CBPM
LCSTPAWAKEKH	CERU	SPLLDIVGGRKA	CAP7	STPAWAKEKHYY	CERU
SGGVTTTPWSLA	CFAB	LDIVGGRKARPR	CAP7	TPAWAKEKHYYI	CERU
IGKSHTEDDIII	CHLE	LWTVQAMPDNAA	CBG	AWAKEKHYYIGI	CERU
GKSHTEDDIIIA	CHLE	VQAMPNAAAYVN	CBG	WAKEKHYYIGII	CERU
SHTEDDII IATK	CHLE	GLLLPLVAALDF	CBPM	GLLSGGVTTTPW	CFAB
HTEDDII IATKN	CHLE	PLVAALDFNYHR	CBPM	GGVTTTPWSLAR	CFAB
ALINKGQACFCD	CO6	AALDFNYHRQEG	CBPM	GVTTTPWSLARP	CFAB
LINKGQACFCDH	CO6	ALDFNYHRQEGM	CBPM	TTTPWSLARPQG	CFAB
INKGQACFCDHY	CO6	FLCSTPAWAKEK	CERU	TPWSLARPQGSC	CFAB
GQACFCDHYAWT	CO6	CSTPAWAKEKHYY	CERU	KSHTEDDII IAT	CHLE
LCLPAVWGDCGL	DAF	PAWAKEKHYYIG	CERU	EDDII IATKNGK	CHLE
GDCGLPPDVPNA	DAF	AKEKHYYIGIIE	CERU	NALINKGQACFC	CO6
LSPTSLAETVHC	EGLN	KEKHYYIGI IET	CERU	NKGQACFCDHYA	CO6
TSLAETVHCDLQ	EGLN	LLSGGVTTTPWS	CFAB	KGQACFCDHYAW	CO6
LAETVHCDLQPV	EGLN	LSGGVTTTPWSL	CFAB	QACFCDHYAWTQ	CO6
CLVGTISLACND	FGF7	VTTTPWSLARPQ	CFAB	ACFCDHYAWTQW	CO6
VGTISLACNDMT	FGF7	TTPWSLARPQGS	CFAB	LLCLPAVWGDCG	DAF
GTISLACNDMTP	FGF7	CMLIGKSHTEDD	CHLE	CLPAVWGDCGLP	DAF
ISLACNDMTPEQ	FGF7	MLIGKSHTEDDI	CHLE	LPAVWGDCGLPP	DAF
VGTAWTADSGEG	FIBA	LIGKSHTEDDII	CHLE	AVWGDCGLPPDV	DAF
TADSGEGDFLAE	FIBA	TEDDII IATKNG	CHLE	VWGDCGLPPDVP	DAF
ADSGEGDFLAE	FIBA	CFCDHYAWTQWT	CO6	WGDCGLPPDVPN	DAF
STGASKSKRQAQ	FINC	PAVWGDCGLPPD	DAF	DCGLPPDVPNAQ	DAF

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swisshot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
ASKSKRQAQQMV	FINC	SLSPTSLAETVH	EGLN	CSLSPTSLAETV	EGLN
RQAQQMVQPQSP	FINC	PTSLAETVHCDL	EGLN	SPTSLAETVHCD	EGLN
HSAPDVQDCPEC	GLHA	SLAETVHCDLQP	EGLN	AETVHCDLQPVG	EGLN
SEIVSISALSTT	GLPB	ETVHCDLQPVGP	EGLN	LVGTISLACNDM	FGF7
IVSISALSTTEV	GLPB	LSVVGTAWTADS	FIBA	TISLACNDMTPE	FGF7
VSISALSTTEVA	GLPB	SVVGTAWTADSG	FIBA	SLACNDMTPEQM	FGF7
LSTTEVAMHTST	GLPB	VVGTAWTADSGE	FIBA	LACNDMTPEQMA	FGF7
AALVACARGDPA	GLYP	GTAWTADSGEGD	FIBA	ACNDMTPEQMAT	FGF7
LVACARGDPASK	GLYP	TAWTADSGEGDF	FIBA	CNDMTPEQMATN	FGF7
GDPASKSRSCGE	GLYP	TGASKSKRQAQQ	FINC	AWTADSGEGDFL	FIBA
DPASKSRSCGEV	GLYP	SKSKRQAQQMVQ	FINC	WTADSGEGDFLA	FIBA
SSQHWSYGLRPG	GONL	QAQQMVQPQSPV	FINC	GASKSKRQAQQM	FINC
SQHWSYGLRPGG	GONL	SVFLHVLHSAPD	GLHA	KSKRQAQQMVQP	FINC
VLLQCCSAYKLV	GP39	VFLHVLHSAPDV	GLHA	SKRQAQQMVQPQ	FINC
LLQCCSAYKLV	GP39	FLHVLHSAPDVQ	GLHA	KRQAQQMVQPQS	FINC
SAYKLVICYTSW	GP39	LHVLHSAPDVQD	GLHA	LHSAPDVQDCPE	GLHA
ESWAIKEEHVII	HA2R	HVLHSAPDVQDC	GLHA	SAPDVQDCPECT	GLHA
SWAIKEEHVIIQ	HA2R	VLHSAPDVQDCP	GLHA	LSEIVSISALST	GLPB
AIKEEHVIIQAE	HA2R	APDVQDCPECTL	GLHA	EIVSISALSTTE	GLPB
SAWGGSKGPLDQ	HEP2	SALSTTEVAMHT	GLPB	SISALSTTEVAM	GLPB
WGGSKGPLDQLE	HEP2	ALSTTEVAMHTS	GLPB	ISALSTTEVAMH	GLPB
GGSKGPLDQLEK	HEP2	CARGDPASKSRS	GLYP	ALVACARGDPAS	GLYP
ALMISMISADSH	HIS1	WCVEGCSSQHWS	GONL	VACARGDPASKS	GLYP
MISMISADSHEK	HIS1	EGCSSQHWSYGL	GONL	ACARGDPASKSR	GLYP
ISADSHEKRHHG	HIS1	GCSSQHWSYGLR	GONL	ARGDPASKSRSC	GLYP
ADSHEKRHHGYR	HIS1	CSSQHWSYGLRP	GONL	RGDPASKSRSCG	GLYP
VFLASPLVAIWE	I12B	LVLLQCCSAYKL	GP39	TWCVEGCSSQHW	GONL
FLASPLVAIWEL	I12B	LQCCSAYKLV	GP39	CVEGCSSQHWSY	GONL
ASPLVAIWELKK	I12B	CSAYKLVICYTS	GP39	VEGCSSQHWSYG	GONL
VAIWELKKDVYV	I12B	MSAQESWAIKEE	HA2R	QHWSYGLRPGGK	GONL
AIWELKKDVYVV	I12B	SAQESWAIKEEH	HA2R	QCCSAYKLVICY	GP39
IWELKKDVYVVE	I12B	QESWAIKEEHVI	HA2R	CCSAYKLVICYT	GP39
SCSVGCDLPQTH	INA2	WAIKEEHVIIQA	HA2R	AYKLVICYTSWS	GP39
SVGCDLPQTHSL	INA2	ITSAWGGSKGPL	HEP2	YKLVICYTSWSQ	GP39
IVLGLSLGCYCQD	ING	AWGGSKGPLDQL	HEP2	LMSAQESWAIKE	HA2R
VLGLSLGCYCQDP	ING	SMISADSHEKRH	HIS1	AQESWAIKEEHV	HA2R
GSLGCYCQDPYV	ING	MISADSHEKRHH	HIS1	IKEEHVIIQAEF	HA2R
CYCQDPYVKEAE	ING	SADSHEKRHHGY	HIS1	FLIITSAWGGSK	HEP2

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swisshot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
PDPAAAFVNQHL	INS	DSHEKRHHGYRR	HIS1	LIITSAWGGSKG	HEP2
PAAAFVNQHLCG	INS	LASPLVAIWELK	I12B	IITSAWGGSKGP	HEP2
AAAFVNQHLCGS	INS	SCKSSCSVGC DL	INA2	TSAWGGSKGPLD	HEP2
AAFVNQHLCGSH	INS	SSCSVGC DLPQT	INA2	GSKGPLDQLEKG	HEP2
AFVNQHLCGSHL	INS	CSVGC DLPQTHS	INA2	LMISMISADSHE	HIS1
YNVGLPEAKIFS	ITA2	VGC DLPQTHSLG	INA2	ISMISADSHEKR	HIS1
ALATSLGFNLDT	ITAX	CDLPQTHSLGSR	INA2	SPLVAIWELKKD	I12B
LATSLGFNLDTTE	ITAX	CIVLGLSLGCYCQ	ING	PLVAIWELKKDV	I12B
GFNLDTTEELTAF	ITAX	LGS LGCYCQDPY	ING	LVAIWELKKDVY	I12B
LFPAILAKQFTK	LCA	GCYCQDPYVKEA	ING	CKSSCSVGC DLP	INA2
VLGTTHGLFGKL	LIPG	LWGPDPAAAFVN	INS	KSSCSVGC DLPQ	INA2
HGLFGKLHPGSP	LIPG	QGILNCCLAYNV	ITA2	GCDLPQTHSLGS	INA2
LMFLSQSQQGEA	LITA	GILNCCLAYNVG	ITA2	LCIVLGLSLGCYC	ING
FLSQSQQGEAQ	LITA	LNCCLAYNVGLP	ITA2	SLGCYCQDPYVK	ING
LSQSQQGEAQTE	LITA	NCCLAYNVGLPE	ITA2	LGCYCQDPYVKE	ING
QGGEAQTELPQA	LITA	LAYNVGLPEAKI	ITA2	WGPDPAAAFVNQ	INS
GGEAQTELPQAR	LITA	FTALATSLGFNL	ITAX	GPDPAAAFVNQH	INS
ARPHALSSAAMF	LMP1	TALATSLGFNL	ITAX	DPAAAFVNQHLC	INS
HALSSAAMFMVK	LMP1	TSLGFNLDTTEEL	ITAX	FVNQHLCGSHLV	INS
LSSAAMFMVKN	LMP1	SLGFNLDTTEELT	ITAX	ILNCCLAYNVGL	ITA2
AMFMVKNNGTA	LMP1	GILFPAILAKQF	LCA	CCLAYNVGLPEA	ITA2
AHPDAQAEVRLS	LU	ILFPAILAKQFT	LCA	CLAYNVGLPEAK	ITA2
HPDAQAEVRLSV	LU	PAILAKQFTKCE	LCA	AYNVGLPEAKIF	ITA2
QAEVRLSVPLV	LU	AILAKQFTKCEL	LCA	ATSLGFNLDTTE	ITAX
EVRLSVPLVEV	LU	ILAKQFTKCELS	LCA	LGFNLDTTEELTA	ITAX
SVTVQGKVFERC	LYC	AKQFTKCELSQL	LCA	FNLDTTEELTAFR	ITAX
GKVFERCELART	LYC	KQFTKCELSQLL	LCA	FPAILAKQFTKC	LCA
VAVCTADFFRDE	MDP1	ISVLGTTHGLFG	LIPG	LAKQFTKCELSQ	LCA
AVCTADFFRDEA	MDP1	SVLGTTHGLFGK	LIPG	TTHGLFGKLHPG	LIPG
ADFFRDEAERIM	MDP1	LGTTTHGLFGKLH	LIPG	THGLFGKLHPGS	LIPG
DFFRDEAERIMR	MDP1	GTTHGLFGKLHP	LIPG	LFGKLHPGSPEV	LIPG
CCCCPRVAGVPG	MU18	GLFGKLHPGSPE	LIPG	MFLSQSQQGEAQ	LITA
CPRVAGVPGAE	MU18	SQSQQGEAQTEL	LITA	SQSQQGEAQTELPQ	LITA
VPGEAEQPAPPEL	MU18	QSQSQGEAQTELP	LITA	PHALSSAAMFMV	LMP1
LFLTPGILCICP	OMGP	QEAQTELPQARI	LITA	ALSSAAMFMVKN	LMP1
LTPGILCICPLQ	OMGP	RPHALSSAAMFM	LMP1	SSAAMFMVKNGN	LMP1
TPGILCICPLQC	OMGP	SAAMFMVKNNG	LMP1	AAMFMVKNNGNT	LMP1
GILCICPLQCIC	OMGP	VLGAVRSYALEL	LMP2	GAVRSYALELNL	LMP2

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swissprot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
ILCICPLQCICT	OMGP	LGAVRSYALELN	LMP2	YALELNLTDSEN	LMP2
FGLLQAHGNLVN	PA2M	AVRSYALELNLT	LMP2	ALELNLTDSENA	LMP2
GLLQAHGNLVNF	PA2M	VRSYALELNLTDS	LMP2	PDAQAEVRLSVP	LU
AHGNLVNFHRMI	PA2M	RSYALELNLTDS	LMP2	LLSVTVQGKVF	LYC
HGNLVNFHRMIK	PA2M	SYALELNLTDS	LMP2	VQGKVFERCELA	LYC
GLVALSECIMYK	PEPA	LELNLTDSENAT	LMP2	LVAVCTADFFRD	MDP1
SECIMYKVPLIR	PEPA	LAHPDAQAEVR	LU	VCTADFFRDEAE	MDP1
AVVKVPLKFKFS	PEPC	AAHPDAQAEVRL	LU	CTADFFRDEAER	MDP1
LLLPSLADGATP	PPA5	DAQAEVRLSVPP	LU	TADFFRDEAERI	MDP1
LPSLADGATPAL	PPA5	AQAEVRLSVPL	LU	CCCPRVAGVPGE	MU18
ATPALRFVAVGD	PPA5	AEVRLSVPLVE	LU	CCPRVAGVPGEA	MU18
GTCLTNSLVPEK	PPBT	VLLSVTVQGKVF	LYC	RVAGVPGEAEQP	MU18
LLCQSVAPLPIC	PRL	LSVTVQGKVF	LYC	AGVPGEAEQPAP	MU18
LCQSVAPLPICP	PRL	VTVQGKVF	LYC	GVPGEAEQPAP	MU18
PLPICPGGAARC	PRL	TVQGKVF	LYC	FLTPGILCICPL	OMGP
MLALGTLAEAQ	PS2	QKVF	LYC	CICPLQCICTER	OMGP
LALGTLAEAQTE	PS2	KVF	LYC	ICPLQCICTERH	OMGP
ALGTLAEAQ	PS2	W	MDP1	LQAHGNLVNFHR	PA2M
LAEAQ	PS2	SL	MDP1	G	PA2M
EAQ	PS2	PR	MU18	N	PA2M
TLCNASCYFIPN	PSSP	VAGVPGEAEQPA	MU18	ECIMYKVPLIRK	PEPA
CFLT	PTHY	PGILCICPLQCI	OMGP	IMYKVPLIRKKS	PEPA
TKSDGKSVKRS	PTHY	LCICPLQCICTE	OMGP	LVCLQLLEAAVV	PEPC
VDTAEAGKKEK	PTN	IFGLLQAHGNLV	PA2M	LLEAAVVKVPLK	PEPC
EAGKKEKPEK	PTN	LLQAHGNLVNFH	PA2M	AAVVKVPLKFK	PEPC
GKKEKPEK	PTN	QAHGNLVNFHRM	PA2M	PSLADGATPALR	PPA5
NQFSRAVADSWM	REL2	LGLVALSECIMY	PEPA	SLADGATPALRF	PPA5
QFSRAVADSWME	REL2	LVALSECIMYKV	PEPA	LADGATPALRFV	PPA5
FSRAVADSWMEE	REL2	VALSECIMYKVP	PEPA	DGATPALRFVAV	PPA5
RAVADSWMEEVI	REL2	ALSECIMYKVPL	PEPA	GATPALRFVAVG	PPA5
VADSWMEEVIKL	REL2	LSECIMYKVPLI	PEPA	TCLTNSLVPEKE	PPBT
LVLGVSSRSFFS	SAA	CIMYKVPLIRK	PEPA	CLTNSLVPEKEK	PPBT
LGVSSRSFFSFL	SAA	VCLQLLEAAVVK	PEPC	LVPEKEKDPKYW	PPBT
LTSLLEAFAHTD	SAMP	CLQLLEAAVVKV	PEPC	LLCQSVAPLP	PRL
TSLLEAFAHTDL	SAMP	LQLLEAAVVKVP	PEPC	VAPLPICPGGAA	PRL
LLEAFAHTDL	SAMP	QLLEAAVVKVPL	PEPC	APLPICPGGAAR	PRL
AFAHTDL	SAMP	LEAAVVKVPLK	PEPC	LPICPGGAARCQ	PRL
FAHTDL	SAMP	EAAVVKVPLK	PEPC	L	PS2

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swissprot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
AHTDLSGKVFVF	SAMP	LLPSLADGATPA	PPA5	GTLAEAQTETCT	PS2
HTDLSGKVFVFP	SAMP	ADGATPALRFVA	PPA5	TLAEAQTETCTV	PS2
AHLKKPSQLSSF	SAP3	AIGTCLTNSLVP	PPBT	TFVTLCNASCYF	PSSP
KKPSQLSSFSWD	SAP3	IGTCLTNSLVPE	PPBT	FVTLCNASCYFI	PSSP
VGLAAVNMPVD	SG1	LTNSLVPEKEKD	PPBT	VTLCNASCYFIP	PSSP
VNSMPVDNRNHN	SG1	TNSLVPEKEKDP	PPBT	LCNASCYFIPNE	PSSP
SMPVDNRNHNEG	SG1	NSLVPEKEKDPK	PPBT	CNASCYFIPNEG	PSSP
WLQEGSAFPTIP	SOMA	SLVPEKEKDPKY	PPBT	ICFLTKSDGKSV	PTHY
AFPTIPLSRLFD	SOMA	CQSVAPLPICPG	PRL	LTKSDGKSVKKR	PTHY
FPTIPLSRLFDN	SOMA	QSVAPLPICPGG	PRL	KSDGKSVKKRSV	PTHY
FFLWEAESAHAAS	STS	SVAPLPICPGGA	PRL	SDGKSVKKRSVS	PTHY
WEAESAASRPN	STS	SMLALGTLAEAQ	PS2	GKSVKKRSVSEI	PTHY
ESHAASRPNIIL	STS	AEAQTETCTVAP	PS2	KSVKKRSVSEIQ	PTHY
LLGVLGALTEMC	TCO2	ATFVTLCNASCY	PSSP	AVDTAEAGKKEK	PTN
AFLALATEGGVL	TENA	NASCYFIPNEGV	PSSP	TAEAGKKEKPEK	PTN
LALATEGGVLKK	TENA	ASCYFIPNEGVP	PSSP	AEAGKKEKPEKK	PTN
GLHATIHCASPE	THBG	SCYFIPNEGVPG	PSSP	AGKKEKPEKKVK	PTN
HATIHCASPEGK	THBG	FLTKSDGKSVKK	PTHY	AVADSWMEEVIK	REL2
HCASPEGKVTAC	THBG	DGKSVKKRSVSE	PTHY	DSWMEEVIKLCG	REL2
LIAPSRACVCVP	TIM1	LAAVDTAEAGKK	PTN	SSRSFFSFLGEA	SAA
RACVCVPPHPQT	TIM1	AAVDTAEAGKKE	PTN	SRSFFSFLGEAF	SAA
CLAGRRRRSVQW	TRFL	DTAEAGKKEKPE	PTN	RSFFSFLGEAFD	SAA
LTFVAAAVAAPF	TRY2	LNQFSRAVADSW	REL2	SLLEAFAHTDLS	SAMP
FVAAAVAAPFDD	TRY2	SRAVADSWMEEV	REL2	HLKKPSQLSSFS	SAP3
AVAAPFDDDDKI	TRY2	ADSWMEEVIKLC	REL2	KPSQLSSFSWDN	SAP3
VQALQQAGIVGG	TRYA	CSLVLGVSRSRFS	SAA	PSQLSSFSWDNC	SAP3
QALQQAGIVGGQ	TRYA	SLVLGVSSRSFF	SAA	SSFSWDNCDEGK	SAP3
QAGIVGGQEAPR	TRYA	VLGVSSRSRFSF	SAA	AVGLAAVNMPV	SG1
AGIVGGQEAPRS	TRYA	GVSSRSRFSFLG	SAA	AAVNMPVDNRN	SG1
GIVGGQEAPRSK	TRYA	VSSRSRFSFLGE	SAA	AVNSMPVDNRNH	SG1
IVGGQEAPRSKW	TRYA	LEAFAHTDLSGK	SAMP	LPWLQEGSAFPT	SOMA
SEAGPTGTGESK	TTHY	EFAHTDLSGKV	SAMP	QEGSAFPTIPLS	SOMA
LVSDSKGSNEL	UROK	LKKPSQLSSFSW	SAP3	EGSAFPTIPLSR	SOMA
DSKGSNELHQVP	UROK	SQLSSFSWDNCD	SAP3	SAFPTIPLSRLF	SOMA
KGSNELHQVPSN	UROK	QLSSFSWDNCDE	SAP3	LCLAGRALAAPQ	SPRC
GSNELHQVPSNC	UROK	LSSFSWDNCDEG	SAP3	CLAGRALAAPQQ	SPRC
HAKWSQAAPMAE	VEGF	GLAAVNMPVDN	SG1	AGRALAAPQQEA	SPRC
AKWSQAAPMAEG	VEGF	LAAVNMPVDNR	SG1	GRALAAPQQEAL	SPRC

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swisshot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
KWSQAAPMAEGG	VEGF	NSMPVDNRNHNE	SG1	LAAPQQEALPDE	SPRC
WSQAAPMAEGGG	VEGF	MPVDNRNHNEGM	SG1	EAESHAASRPNI	STS
FGHALERGRDYE	VTDB	PWLQEGSAFPTI	SOMA	SHAASRPNIILV	STS
LERGRDYEKNKV	VTDB	LQEGSAFPTIPL	SOMA	HAASRPNIILVM	STS
ALLAWVALADQE	VTNC	GSAFPTIPLSRL	SOMA	GVLGALTEMCEI	TCO2
LLAWVALADQES	VTNC	LAGRALAAPQQE	SPRC	LGALTEMCEIPE	TCO2
AWVALADQESCK	VTNC	RALAAPQQEALP	SPRC	ALTEMCEIPEMD	TCO2
LADQESCKGRCT	VTNC	ALAAPQQEALPD	SPRC	LTEMCEIPEMDS	TCO2
AVPQENQDGRYS	ZA2G	AAPQQEALPDET	SPRC	EMCEIPEMDSHL	TCO2
PQENQDGRYSLT	ZA2G	APQQEALPDETE	SPRC	ATEGGVLKKVIR	TENA
LLAGAHAEFPGC	PLTP	LFFLWEAESHAA	STS	TEGGVLKKVIRH	TENA
LAGAHAEFPGCK	PLTP	FLWEAESHAASR	STS	GGVLKKVIRHKR	TENA
AGAHAEFPGCKI	PLTP	LWEAESHAASRP	STS	IHCASPEGKVTA	THBG
		AESHAASRPNI I	STS	ASPEGKVTACHS	THBG
		LGVLGALTEMCE	TCO2	LWLIAPSRACTC	TIM1
		VLGALTEMCEIP	TCO2	WLIAPSRACTCV	TIM1
		GALTEMCEIPEM	TCO2	IAPSRACTCVPP	TIM1
		TEMCEIPEMDSH	TCO2	APSRACTCVPPH	TIM1
		FLALATEGGVLK	TENA	ACTCVPPHPQTA	TIM1
		ALATEGGVLKKV	TENA	LGALGLCLAGR	TRFL
		LATEGGVLKKVI	TENA	GALGLCLAGR	TRFL
		EGGVLKKVIRHK	TENA	ALGLCLAGR	TRFL
		GVLKKVIRHKRQ	TENA	LAGRRRRSVQWC	TRFL
		LGLHATIHCASP	THBG	AGRRRRSVQWCA	TRFL
		LHATIHCASPEG	THBG	GRRRRSVQWCAV	TRFL
		ATIHCASPEGKV	THBG	AAVAAPFDDDDK	TRY2
		TIHCASPEGKVT	THBG	ALQQAGIVGGQE	TRYA
		CASPEGKVTACH	THBG	GLVVFSEAGPTG	TTHY
		PSRACTCVPPHP	TIM1	LVVFSEAGPTGT	TTHY
		SRACTCVPPHPQ	TIM1	EAGPTGTGESKC	TTHY
		CTCVPPHPQTAF	TIM1	AGPTGTGESKCP	TTHY
		LGLCLAGR	TRFL	VLVVS	UROK
		GLCLAGR	TRFL	SDSKGSNELHQV	UROK
		LCLAGR	TRFL	SNELHQVPSNCD	UROK
		TFVAAA	TRY2	LHHAKWSQAAPM	VEGF
		VAAA	TRY2	SQAAPMAEGGGQ	VEGF
		AAA	TRY2	QAAPMAEGGGQN	VEGF
		VAAF	TRY2	LAVAFGHALERG	VTDB

TABELLE 31. Aufteilung der Nicht-Schnittstellensequenzen in die drei Gruppen der Kreuzevaluierung mit entsprechenden Swissprot-Abkürzungen.

Gruppe 1	ID	Gruppe 2	ID	Gruppe 3	ID
		AAPFDDDDKIVG	TRY2	GHALERGRDYEK	VTDB
		APFDDDDKIVGG	TRY2	LAWVALADQESC	VTNC
		PVQALQQAGIVG	TRYA	VALADQESCKGR	VTNC
		LQQAGIVGGQEA	TRYA	LLLLGPAVPQEN	ZA2G
		QQAGIVGGQEAP	TRYA	LLLGPAVPQENQ	ZA2G
		AGLVFVSEAGPT	TTHY	LLGPAVPQENQD	ZA2G
		VFVSEAGPTGTG	TTHY	LGPVPQENQDQD	ZA2G
		FVSEAGPTGTGE	TTHY	GPAVPQENQDGR	ZA2G
		VSEAGPTGTGES	TTHY	PAVPQENQDGRY	ZA2G
		GPTGTGESKCPL	TTHY	VPQENQDGRYSL	ZA2G
		VVSDSKGSNELH	UROK	QENQDGRYSLTY	ZA2G
		VSDSKGSNELHQ	UROK	LALLAGAHAEFP	PLTP
		SKGSNELHQVPS	UROK	GAHAEFPGCKIR	PLTP
		HHAKWSQAAPMA	VEGF	AHAEFPGCKIRV	PLTP
		AAPMAEGGGQNH	VEGF	AEPFGCKIRVTS	PLTP
		APMAEGGGQNH	VEGF	EFPFGCKIRVTSK	PLTP
		LLAVAFGHALER	VTDB		
		AVAFGHALERGR	VTDB		
		VAFGHALERGRD	VTDB		
		AFGHALERGRDY	VTDB		
		HALERGRDYEKN	VTDB		
		ALERGRDYEKNK	VTDB		
		WVALADQESCKG	VTNC		
		ALADQESCKGRC	VTNC		
		ADQESCKGRCTE	VTNC		
		DQESCKGRCTEG	VTNC		
		ALLAGAHAEFPG	PLTP		
		HAEFPGCKIRVT	PLTP		

